Key result
Elevated PAWP linked to smaller mPAP reductions after BPA in CTEPH, with similar survival.
Why the study?
The study aimed to evaluate whether elevated pulmonary arterial wedge pressure, associated with left ventricular dysfunction, influences the effectiveness and safety of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension.
Does elevated PAWP affect the effectiveness and safety of BPA in patients with CTEPH?
Cohort (n=170)
Does elevated PAWP affect the effectiveness and safety of BPA in patients with CTEPH?
Answers are grounded in this paper and cite their sources.
In patients with CTEPH undergoing balloon pulmonary angioplasty, elevated PAWP is associated with attenuated hemodynamic and functional improvements but does not negatively impact procedural safety or long-term survival.
BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare condition caused by thromboembolic occlusions of the pulmonary arteries and characterized by elevated pulmonary pressure, vascular remodelling, and right ventricular overload, which can be treated effectively with balloon pulmonary angioplasty (BPA). The study aimed to evaluate whether elevated pulmonary arterial wedge pressure (PAWP), associated with left ventricular dysfunction, influences the effectiveness and safety of BPA treatment. RESEARCH QUESTION: Does elevated PAWP affect the effectiveness and safety of BPA in patients with CTEPH? STUDY DESIGN AND METHODS: A retrospective analysis was conducted of 170 patients with CTEPH treated with BPA. Patients were classified into 2 groups: those with normal PAWP and those with elevated PAWP. Hemodynamic parameters, exercise capacity, treatment outcomes, and safety profiles were compared between the groups. Multivariate analysis of overall survival also was performed. RESULTS: Elevated PAWP was present in 13.5% of patients. The elevated PAWP group was older, had a higher BMI, had higher elevated baseline troponin levels, and had a greater burden of comorbidities-including diabetes, atrial fibrillation, deep vein thrombosis, and chronic kidney disease-than patients with normal PAWP. After treatment, patients with elevated PAWP exhibited significantly smaller reduction in mean pulmonary artery pressure (P = .026) and lower improvement in pulmonary arterial compliance (P = .002) and 6-minute walk distance (P = .011) compared with those with normal PAWP. No significant differences were found in overall survival or adverse event rates observed between the groups. INTERPRETATION: Elevated PAWP, likely reflecting coexisting left-sided heart dysfunction, was associated with reduced hemodynamic and functional benefits resulting from BPA in patients with CTEPH. Nevertheless, it did not compromise procedural safety or long-term survival, suggesting that BPA remains a viable option in this subgroup, albeit with more modest clinical gains.
No takes yet. Share an insight, caveat, or question.
Szwed et al. (2025) conducted a cohort in Chronic thromboembolic pulmonary hypertension (CTEPH) (n=170). Elevated pulmonary arterial wedge pressure (PAWP) vs. Normal PAWP was evaluated on Reduction in mean pulmonary artery pressure (p=0.026). Elevated PAWP in CTEPH patients treated with balloon pulmonary angioplasty was associated with smaller reductions in mean pulmonary artery pressure but similar overall survival.
Synapse has enriched 10 related papers. Consider them for comparative context: